Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
Portfolio Pulse from
Keros Therapeutics has voluntarily halted dosing in certain treatment arms of its Phase 2 TROPOS trial for cibotercept due to safety concerns, specifically pericardial effusion adverse events.
December 12, 2024 | 11:15 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Keros Therapeutics has paused dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms of its Phase 2 TROPOS trial for cibotercept due to safety concerns, specifically pericardial effusion adverse events.
The halting of dosing in the trial due to safety concerns is likely to negatively impact investor sentiment and the stock price in the short term. Safety issues in clinical trials can lead to delays and increased scrutiny, affecting the company's progress and valuation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100